Literature

Assessment of correlation of response to Drug-Eluting Bead doxorubicin (DEBDOX) in explanted liver in patients with HCC listed for orthoptic liver transplantations
Date 28 September 2011
Where presented Asian Pacific HPBA 2011, Melbourne
Author(s) Dr Andrew Holden
Resources

Download file

Patient selection for Drug-Eluting Bead irinotecan (DEBIRI) - the surgical oncologist's perspective
Date 28 September 2011
Where presented Asian Pacific HPBA 2011, Melbourne
Author(s) Dr Robert Martin
Resources

Download file

Feasibility of neoadjuvant Drug-Eluting Bead irinotecan (DEBIRI) for resectable colorectal liver metastases
Date 15 September 2011
Where presented AUGIS 2011, Belfast
Author(s) Mr Stephen Fenwick
Resources

Download file

DEBIRI TACE: Patterns and Predictors of Response
Date 15 September 2011
Where presented AUGIS 2011, Belfast
Author(s) Mr Robert Jones
Resources

Download file

Final results of a prospective randomized trial assessing survival at 2 years of DEBIRI vs FOLFIRI in patients with hepatic metastases from colorectal cancer
Date 12 September 2011
Where presented CIRSE 2011, Munich
Author(s) Prof G Fiorentini
Resources

Download file

DEBIRI pharmacokinetics in an animal model
Date 12 September 2011
Where presented CIRSE 2011, Munich
Author(s) Prof T de Baere
Resources

Download file

Five-year survival data of HCC patients treated with DC Bead at Athens Centre
Date 12 September 2011
Where presented CIRSE 2011, Munich
Author(s) Prof K Malagari
Resources

Download file

Treatment of colorectal liver metastases with DC BeadM1: preliminary results
Date 12 September 2011
Where presented CIRSE 2011, Munich
Author(s) Prof P Huppert
Resources

Download file

DC BeadM1: tips and tricks
Date 11 September 2011
Where presented CIRSE 2011, Munich
Author(s) C Aliberti
Resources

Download file

Five-year survival follow-up of 100 HCC patients treated with DC Bead at BCLC: a retrospective analysis
Date 11 September 2011
Where presented CIRSE 2011, Munich
Author(s) Dr Marta Burrel
Resources

Download file

Clinical results of phase II trial of sorafenib combined with Drug-Eluting Bead doxorubicin (DEBDOX) for patients with hepatocellular carcinoma
Date 11 September 2011
Where presented CIRSE 2011, Munich
Author(s) Prof Jeff Geschwind
Resources

Download file

Abstract: Early stage HCC: Update on recent trials
Date 10 September 2011
Where presented CIRSE 2011, Munich
Author(s) R Lencioni
Resources

Download file

Abstract: Early Stage HCC: How to ablate - current options
Date 10 September 2011
Where presented CIRSE 2011, Munich
Author(s) M Bezzi
Resources

Download file

Abstract: Early stage HCC: Segmental transcatheter approach to the early tumour
Date 10 September 2011
Where presented CIRSE 2011, Munich
Author(s) Y Arai
Resources

Download file

Abstract: Early stage HCC: Imaging and staging
Date 10 September 2011
Where presented CIRSE 2011, Munich
Author(s) D Brisbois
Resources

Download file

Asian Experience with Drug-Eluting beads for HCC and Rationale for the TRACER Study
Date 3 September 2011
Where presented International Liver Cancer Association (ILCA) 2011
Author(s) Prof Ronnie Poon
Resources

Download file

Five-year follow up with DEBDOX in intermediate HCC, BCLC experience
Date 3 September 2011
Where presented International Liver Cancer Association (ILCA) 2011, Hong Kong
Author(s) Prof Jordi Bruix
Resources

Download file

Is DEBDOX the new standard for chemoembolisation?
Date 3 September 2011
Where presented International Liver Cancer Association (ILCA) 2011
Author(s) Prof Riccardo Lencioni
Resources

Download file

Overview of HCC management and rationale for SPACE trial
Date 3 September 2011
Where presented International Liver Cancer Association (ILCA) 2011, Hong Kong
Author(s) Prof Josep Llovet
Resources

Download file

Neoadjuvant DEBIRI, Drug-Eluting Bead irinotecan. One year follow-up, pathology and biology of response (symposium presentation)
Where presented June 22-25, 2011, Barcelona
Conference World Congress on Gastrointestinal Cancer (WCGIC)
Author(s) G Poston
Resources

Download file

Page 1 of 12 pages  1 2 3 4 5 >  Last ›

Regulatory notices and product safety data

Worldwide (excluding USA and Canada)

DC Bead® is CE marked and is indicated for the treatment of malignant hypervascular tumours and loading with doxorubicin drug. DC Bead® is also indicated for loading with irinotecan for the treatment of metastatic colorectal cancer (mCRC). For full prescribing information please refer to DC Bead instructions for use.

USA

DC Bead is not currently available for sale or distribution in the USA. DC Bead has not been submitted for approval to the FDA.

Canada

DC Bead® with doxorubicin is indicated for trans-arterial chemoembolization (TACE) of unresectable hepatocellular carcinoma (HCC). DC Bead are also intended to be loaded with irinotecan for the purpose of embolization of vessels supplying malignant colorectal cancer metastasised to the liver (mCRC), and delivery of a local, controlled, sustained dose of irinotecan to the mCRC. For full prescribing information please refer to DC Bead Canada Instructions for Use 

Tawain

DC Bead is approved by the Department of Health and is intended to be loaded with Mayne (Hospira) doxorubicin HCI for the purpose of embolisation of vessels supplying malignant hypervascularised tumour(s), and delivery of a local, controlled, sustained dose of doxorubicin.  DC Bead is also indicated for the embolisation of nidus vessels without medication.  Approved size ranges in Taiwan are 300-500µm and 500-700µm.